# Elanco Animal Health Inc: overview

ELAN · NYSE · CIK 1739104 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elan.md) · [Financials](/companies/elan/financials.md) · [Filings](/companies/elan/filings.md) · [Insiders](/companies/elan/insiders.md)

Latest reported revenue: [$1.37bn](/filings/0001739104-26-000043.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001739104-26-000043).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,030](/filings/0001739104-25-000071.md) | [1,020 d](/filings/0001739104-26-000012.md) | [1,193](/filings/0001739104-26-000030.md) | [1,241](/filings/0001739104-26-000043.md) | [1,137](/filings/0001739104-25-000071.md) | [1,144 d](/filings/0001739104-26-000012.md) | [1,371](/filings/0001739104-26-000030.md) | [1,368](/filings/0001739104-26-000043.md) |
| Gross margin | % | [52.2%](/filings/0001739104-25-000071.md) | [50.9% d](/filings/0001739104-26-000012.md) | [57.3%](/filings/0001739104-26-000030.md) | [57.5%](/filings/0001739104-26-000043.md) | [53.4%](/filings/0001739104-25-000071.md) | [51.5% d](/filings/0001739104-26-000012.md) | [57.3%](/filings/0001739104-26-000030.md) | [58.3%](/filings/0001739104-26-000043.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [35.3%](/filings/0001739104-25-000071.md) | [(0.8%) d](/filings/0001739104-26-000012.md) | [5.6%](/filings/0001739104-26-000043.md) | [0.9%](/filings/0001739104-26-000043.md) | [(3.0%)](/filings/0001739104-25-000071.md) | [(24.1%) d](/filings/0001739104-26-000012.md) | [4.2%](/filings/0001739104-26-000043.md) | [3.9%](/filings/0001739104-26-000043.md) |
| Diluted EPS | $ per share | [0.73](/filings/0001739104-25-000071.md) | not reported | [0.13](/filings/0001739104-26-000030.md) | [0.02](/filings/0001739104-26-000043.md) | [(0.07)](/filings/0001739104-25-000071.md) | not reported | [0.11](/filings/0001739104-26-000030.md) | [0.11](/filings/0001739104-26-000043.md) |
| Free cash flow | $m | [120 d](/filings/0001739104-25-000071.md) | [130 d](/filings/0001739104-26-000012.md) | [(69.0)](/filings/0001739104-26-000030.md) | [180 d](/filings/0001739104-26-000043.md) | [127 d](/filings/0001739104-25-000071.md) | [46.0 d](/filings/0001739104-26-000012.md) | [(38.0)](/filings/0001739104-26-000030.md) | [244 d](/filings/0001739104-26-000043.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,764](/filings/0001739104-24-000009.md) | [4,411](/filings/0001739104-25-000014.md) | [4,417](/filings/0001739104-26-000012.md) | [4,439](/filings/0001739104-26-000012.md) | [4,715](/filings/0001739104-26-000012.md) |
| Gross margin | % | not reported | not reported | [56.3%](/filings/0001739104-26-000012.md) | [54.9%](/filings/0001739104-26-000012.md) | [55.0%](/filings/0001739104-26-000012.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(10.1%)](/filings/0001739104-24-000009.md) | [(1.8%)](/filings/0001739104-25-000014.md) | [(27.9%)](/filings/0001739104-26-000012.md) | [7.6%](/filings/0001739104-26-000012.md) | [(4.9%)](/filings/0001739104-26-000012.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0001739104-24-000009.md) | [(0.16)](/filings/0001739104-25-000014.md) | [(2.50)](/filings/0001739104-26-000012.md) | [0.68](/filings/0001739104-26-000012.md) | [(0.47)](/filings/0001739104-26-000012.md) |
| Free cash flow | $m | [324](/filings/0001739104-24-000009.md) | [281](/filings/0001739104-25-000014.md) | [131](/filings/0001739104-26-000012.md) | [394](/filings/0001739104-26-000012.md) | [284](/filings/0001739104-26-000012.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elan/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $1.66bn | 67,397,025 |  | Reduced −1,547,075 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.40bn | 56,948,819 |  | Added +6,023,453 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.20bn | 48,849,973 |  | Added +1,227,343 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $1.12bn | 45,445,012 |  | Reduced −395,944 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $625.5m | 25,417,271 |  | Added +890,136 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $558.0m | 22,672,312 |  | Added +34,955 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $556.4m | 22,607,532 |  | Added +271,408 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $395.3m | 16,063,046 |  | Added +726,567 |
| [Winslow Capital Management, LLC](/funds/900973.md) | 2026-06-30 | $332.5m | 13,511,127 |  | Reduced −103,228 |
| [Black Creek Investment Management Inc.](/funds/1528593.md) | 2026-06-30 | $321.1m | 13,046,420 |  | Added +2,552,571 |

## Recent filings

[All 1,012 filings](/companies/elan/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 13:06 ET | [10-Q](/filings/0001739104-26-000043.md) | Quarterly report, period 2026-06-30 | 0001739104-26-000043 |
| 2026-08-05 | 10:27 ET | [8-K](/filings/0001739104-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001739104-26-000040 |
| 2026-05-27 | 21:00 ET | [8-K](/filings/0001104659-26-067002.md) | 5.07 Shareholder vote results | 0001104659-26-067002 |
| 2026-05-06 | 13:04 ET | [10-Q](/filings/0001739104-26-000030.md) | Quarterly report, period 2026-03-31 | 0001739104-26-000030 |
| 2026-05-06 | 10:30 ET | [8-K](/filings/0001739104-26-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001739104-26-000027 |
| 2026-04-08 | 14:07 ET | [DEF 14A](/filings/0001739104-26-000016.md) | Proxy statement, period 2025-12-31 | 0001739104-26-000016 |
| 2026-02-24 | 14:19 ET | [10-K](/filings/0001739104-26-000012.md) | Annual report, period 2025-12-31 | 0001739104-26-000012 |
| 2026-02-24 | 11:28 ET | [8-K](/filings/0001739104-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001739104-26-000008 |
| 2026-01-12 | 13:00 ET | [8-K](/filings/0001104659-26-002723.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-002723 |
| 2025-12-09 | 12:45 ET | [8-K](/filings/0001104659-25-119486.md) | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-119486 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001739104-26-000012.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e48dfbe5-1f55-4824-9e3d-b235ecfed79e)

## About the filer

- CIK: 1739104
- Tickers: ELAN
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.